Research
Hormonal
Engineered bacteria producing GLP-1 or butyrate can improve glucose tolerance, insulin sensitivity, and reduce body weight in animal models of obesity and diabetes.
Research shows that engineered gut bacteria can produce hormones like GLP-1 or butyrate to improve metabolism in animals. This is a promising area for future oral treatments for diabetes and obesity, but it is not yet a standard therapy.
ModerateSupportsMEDIUM confidence
An engineered Lactobacillus gasseri that expresses an inactive full-length version of GLP-1 showed that this approach is efficient in a rat model of diabetes... Similarly, an engineered Bacillus subtilis producing butyrate retarded body weight gain induced by a high-fat diet and visceral fat accumulation in mice, improved glucose tolerance and insulin tolerance, thereby reducing liver damage.
Why this rating
Strong preclinical data across multiple models (rats, mice, monkeys), but human clinical data is limited or in early phases.
Source
Engineering bacteria to modulate host metabolism
Dragos Ciocan et al. · Acta Physiologica · 2023
DOI 10.1111/apha.14001
narrative_reviewCited 16×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Engineered E. coli Nissle strains (SYNB1618 and SYNB1934) expressing phenylalanine-degrading enzymes successfully reduce fasting plasma phenylalanine levels in patients with Phenylketonuria (PKU) in Phase 1/2a and Phase 2 trials.Good
- Engineered bacteria (SYNB1020) that overproduce arginine to convert gut ammonia into L-arginine successfully lower systemic ammonia and improve survival in animal models of liver failure, but failed to show efficacy in a Phase Ib/IIa clinical trial for cirrhosis patients.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →